Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis

Mult Scler Relat Disord. 2016 May:7:58-60. doi: 10.1016/j.msard.2016.03.007. Epub 2016 Mar 18.

Abstract

Objective: To provide distribution-based estimates of the minimal clinical important difference (MCID) after slow release fampridine treatment on cognition and functional capacity in people with MS (PwMS).

Method: MCID values were determined after SR-Fampridine treatment in 105 PwMS. Testing included the Timed 25 Foot Walk (T25FW), the Symbol Digit Modalities Test (SDMT), the Six Spot Step Test (SSST), the 9-Hole-Peg-Test (9-HPT), and the 5-Time-Sit-To-Stand test (5-STS).

Results: MCID values: T25FW 17.8% (9.1-17.8), SDMT 17.1% (9.2-17.1), SSST 16.7% (8.5-16.7), 9-HPT 15.3% (0-15.3), and 5-STS 34.6% (16.9-34.6).

Conclusion: This study presents distribution-based estimates of MCID values for the SSST, the 9-HPT, and the 5-STS and confirms MCID estimates for the T25FW and the SDMT.

Keywords: Axonal loss; Change; Demyelination; MCID; Minimal clinically important difference; Multiple sclerosis; Rehabilitation.

MeSH terms

  • 4-Aminopyridine / therapeutic use*
  • Arm / physiopathology
  • Cognition / drug effects*
  • Disability Evaluation*
  • Exercise Test
  • Female
  • Humans
  • Male
  • Middle Aged
  • Motor Activity / drug effects*
  • Motor Activity / physiology
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / physiopathology
  • Multiple Sclerosis / psychology
  • Potassium Channel Blockers / therapeutic use*
  • Reference Values
  • Walking / physiology

Substances

  • Potassium Channel Blockers
  • 4-Aminopyridine